PROTOX THERAPEUTICS, WITH
UVIC-BASED RESEARCH THAT HOLDS PROMISE for prostate
cancer patients, has become the first UVic spin-off
company to be listed on the TSX Venture Exchange.
UVic biochemist Tom Buckley
has engineered a protein—Aerolysin—that
punctures cancer cells. “We believe we
can also tailor Aerolysin so that it can selectively
destroy a variety of other types of cancer cells,” says
Buckley, the new company’s chief scientific
officer. Ongoing research is being conducted
jointly with Johns Hopkins University.
The university’s technology
transfer arm, the Innovation and Development
Corporation, encouraged Buckley to go commercial.
This summer the company began trading after the
close of a $4.5-million public offering. In return
for licensing the technology to Protox, UVic
receives a stake in the company, royalties on
product sales, plus other payments if certain
milestones are reached.
to Ringside contents